TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30609164

Group type: EXPERIMENTAL
Intervention: Oxycodone treatment for 5 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment for 5 days
Number of subjects: 25
Study: 28268064

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg orally twice per day plus trametinib 2 mg orally once per day
Number of subjects: 25
Study: 25097102

Group type: EXPERIMENTAL
Intervention: CG100649 (8-mg loading dose + 2 mg/d, 10-mg loading dose + 4 mg/d, or 12-mg loading dose + 8 mg/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CG100649 (12-mg loading dose + 8 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23756962

Group type: EXPERIMENTAL
Intervention: Toltrazuril 5 % suspension (Baycox®, Bayer)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Diclazuril (Vecoxan®, Janssen‐Cilag)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Untreated control group (C)
Number of subjects: 170
Study: 23193862

Group type: EXPERIMENTAL
Intervention: Cast post and core (base metal, Ni‐Cr)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glass‐fiber post and composite resin core
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbon fiber post with composite resin core
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prefabricated parallel‐sided titanium post and composite resin core
Number of subjects: 100
Study: 19890745

Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg (n = 17)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg/ml (n = 12)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (Control group, n = 13)
Number of subjects: 42
Study: 16502766

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg) + Fexofenadine (60 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fexofenadine (60 mg) alone
Number of subjects: 6
Study: 12770969

Group type: EXPERIMENTAL
Intervention: PACG
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: POAG
Number of subjects: 74

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 74
Study: 10866423

Group type: EXPERIMENTAL
Intervention: Pulsatile normothermic cardiopulmonary bypass (CPB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonpulsatile normothermic cardiopulmonary bypass (CPB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pulsatile normothermic CPB
Number of subjects: 28
Study: 8862223

Group type: EXPERIMENTAL
Intervention: Urinary albumin excretion (UAE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 120
Study: 2033028

Group type: EXPERIMENTAL
Intervention: Bright (2500 lux) full-spectrum fluorescent light with UV
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bright (2500 lux) full-spectrum fluorescent light without UV
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dim (500 lux) light control
Number of subjects: 11
Study: 7013056

Group type: EXPERIMENTAL
Intervention: Levamisole 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 40
Study: 31265163

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily until disease progression
Number of subjects: 81
Study: 27628617

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar puncture (UALP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard lumbar puncture (SLP)
Number of subjects: 43
Study: 26095435

Group type: EXPERIMENTAL
Intervention: 16-week group-based lifestyle intervention
Number of subjects: 32
Study: 22169619

Group type: EXPERIMENTAL
Intervention: Modified gay-specific cognitive behavioral therapy combined with low-cost contingency management (GCBT+CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original gay-specific cognitive behavioral therapy (GCBT)
Number of subjects: 0
Study: 22796581

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg) administered preoperatively and postoperatively
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 151
Study: 20840480

Group type: EXPERIMENTAL
Intervention: Tacrolimus BID (Prograf)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Tacrolimus QD (Advagraf)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Both Tacrolimus QD and BID
Number of subjects: 667
Study: 16949710

Group type: EXPERIMENTAL
Intervention: Single dose of live attenuated hepatitis A vaccine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Booster dose of live attenuated hepatitis A vaccine
Number of subjects: 134
Study: 15590232

Group type: EXPERIMENTAL
Intervention: Shared decision-making approach to PSA screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actual decision-making by patients
Number of subjects: 0
Study: 12149467

Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 6
Study: 10064632

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg orally once daily)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (500/125 mg orally 3 times daily)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 535

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 535
Study: 7497157

Group type: EXPERIMENTAL
Intervention: Attendance at hospital
Number of subjects: 499

Group type: COMPARATOR
Intervention: Attendance at GP surgeries
Number of subjects: 499
Study: 3056477

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 16

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both DDD and VVI pacing
Number of subjects: 16
Study: 31882508

Group type: EXPERIMENTAL
Intervention: StrataXRT® (film-forming silicone gel)
Number of subjects: 56

Group type: COMPARATOR
Intervention: X‐derm® (moisturizing cream)
Number of subjects: 56
Study: 30945097

Group type: EXPERIMENTAL
Intervention: Thoracoscopic subtotal esophagectomy with bilateral cervical lymphadenectomy
Number of subjects: 42
Study: 28430117

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 118
Study: 25545400

Group type: EXPERIMENTAL
Intervention: Metformin XL
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 23276318

Group type: EXPERIMENTAL
Intervention: Daily Diary Composite (DDC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Global Self-Report (GSR)
Number of subjects: 89
Study: 21617330

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 984

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 984
Study: 18298204

Group type: EXPERIMENTAL
Intervention: LED lamp (10 seconds curing time)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halogen lamp (20 seconds curing time)
Number of subjects: 30
Study: 20946173

Group type: EXPERIMENTAL
Intervention: GSNO gel (100 µM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study: 15921511

Group type: EXPERIMENTAL
Intervention: PncOMPC vaccine
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PncPS booster
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (Hepatitis B vaccine)
Number of subjects: 111
Study: 11799385

Group type: EXPERIMENTAL
Intervention: EpiPen Jr (0.15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EpiPen (0.3 mg)
Number of subjects: 0
Study: 10182195

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 662

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 662

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 662

Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 662
Study: 7975870

Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides (HR) at a dose of 1000 mg/day for at least 4 weeks
Number of subjects: 1973

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1973
Study: 3178373

Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25 mg of triazolam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11568587

Group type: EXPERIMENTAL
Intervention: Inlay tympanoplasty
Number of subjects: 70

Group type: COMPARATOR
Intervention: Underlay tympanoplasty
Number of subjects: 70
Study: 30791961

Group type: EXPERIMENTAL
Intervention: MitraClip intervention
Number of subjects: 40
Study: 30279086

Group type: EXPERIMENTAL
Intervention: 2.20 mm uniplanar clear corneal incisions
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2.85 mm uniplanar clear corneal incisions
Number of subjects: 100
Study: 26733083

Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity (EPA) group with individualized exercise programming including personalized step goals and resistance band training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard of Care (SoC) group with general activity goal
Number of subjects: 39
Study: 24865869

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 188
Study: 22336590

Group type: EXPERIMENTAL
Intervention: diet (‐600 kcal) alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diet with exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diet with sibutramine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: baseline fat mass plus change in weight and HOMA(IR) at week 4
Number of subjects: 60
Study: 20130094

Group type: EXPERIMENTAL
Intervention: Low-dose DHA (400 mg/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-dose DHA (1200 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17670879

Group type: EXPERIMENTAL
Intervention: 4 percent articaine with 1:100,000 epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 percent lidocaine with 1:100,000 epinephrine
Number of subjects: 60
Study: 15167512

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Partial thyroidectomy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: I scan post-surgery
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: I treatment
Number of subjects: 149
Study: 12225613

Group type: EXPERIMENTAL
Intervention: Pentaglobin (5 ml/kg per day for 3 consecutive days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (standard sepsis therapy without immunoglobulin)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pentaglobin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 9620108

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 7522200

Group type: EXPERIMENTAL
Intervention: CT‐RT group (n = 94)
Number of subjects: 184

Group type: COMPARATOR
Intervention: RT group (n = 90)
Number of subjects: 184
Study: 2537433

Group type: EXPERIMENTAL
Intervention: Dacron grafts
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ePTFE grafts
Number of subjects: 12
Study: 5338377

Group type: EXPERIMENTAL
Intervention: 1-3 injections of 1 ml of aluminium-phosphate-adsorbed tetanus toxoid more than 6 weeks apart
Number of subjects: 1618

Group type: COMPARATOR
Intervention: 2 or 3 injections of influenza-virus vaccine
Number of subjects: 1618
Study: 31813770

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central obesity (CO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adiposity metrics (BMI, WC, CO)
Number of subjects: 0
Study: 28958022

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) for overweight participants (BMI < 30 kg/m2)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) for obese participants (BMI ≥ 30 kg/m2)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) overall
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Control condition (Diabetes Support and Education - DSE)
Number of subjects: 1091
Study: 28257886

Group type: EXPERIMENTAL
Intervention: Payment for Performance (P4P)
Number of subjects: 200
Study: 26677086

Group type: EXPERIMENTAL
Intervention: Periodized hydrogymnastics exercise program (12 weeks, 5 times a week, 50 minutes per session, heart rate reserve 40-50% for weeks 1-6, 50-60% for weeks 7-12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise)
Number of subjects: 26
Study: 23470301

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Higher-Volume Moderate-Intensity Endurance Exercise (END)
Number of subjects: 22
Study: 21600165

Group type: EXPERIMENTAL
Intervention: Quadruple regimen (PPI + bismuth + amoxicillin + furazolidone, 10 days) plus dental plaque removal treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Quadruple regimen (PPI + bismuth + amoxicillin + furazolidone)
Number of subjects: 104
Study: 18082960

Group type: EXPERIMENTAL
Intervention: Microskin (sprayed on skin camouflage) for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microskin (sprayed on skin camouflage) for 5 weeks (wait-list group after initial 7 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microskin (sprayed on skin camouflage)
Number of subjects: 20
Study: 15951393

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 809

Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 809
Study: 12835542

Group type: EXPERIMENTAL
Intervention: Silver-coated textiles
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cotton
Number of subjects: 15
Study: 10506598

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m(2) every 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paclitaxel 250 mg/m(2) with amifostine 910 mg/m(2)
Number of subjects: 40
Study: 8895273

Group type: EXPERIMENTAL
Intervention: Chloroprocaine with fentanyl 3 micrograms/mL (60 micrograms)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Chloroprocaine
Number of subjects: 56
Study: 1803834

Group type: EXPERIMENTAL
Intervention: Ranitidine (Glaxo's formulation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (Veteran's formulation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (both formulations)
Number of subjects: 12
Study: 6133153

Group type: EXPERIMENTAL
Intervention: Tobramycin-ticarcillin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Netilmicin-ticarcillin
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 254
Study: 30626424

Group type: EXPERIMENTAL
Intervention: Intravenous administration of ATP combined with fluoxetine (20 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous administration of PCr combined with fluoxetine (20 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (placebo) combined with fluoxetine (20 mg/day)
Number of subjects: 42
Study: 30227457

Group type: EXPERIMENTAL
Intervention: 30-min arm-cranking exercise at 50% V̇O2max (A-trial)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 30-min leg-cycling exercise at 50% V̇O2max (C-trial)
Number of subjects: 14
Study: 26796660

Group type: EXPERIMENTAL
Intervention: Spray coagulation
Number of subjects: 151

Group type: COMPARATOR
Intervention: Forced coagulation
Number of subjects: 151
Study: 25195134

Group type: EXPERIMENTAL
Intervention: Docetaxel (D) plus Prednisone (P) regimens (standard therapy)
Number of subjects: 7677

Group type: EXPERIMENTAL
Intervention: Docetaxel (D) combinations (D + other drug combinations)
Number of subjects: 7677

Group type: EXPERIMENTAL
Intervention: All trials and arms as a single unit
Number of subjects: 7677
Study: 21987581

Group type: EXPERIMENTAL
Intervention: Prednisolone phosphate, 1%, as adjunctive therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo as adjunctive therapy
Number of subjects: 500
Study: 19188272

Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation with maintained unsupported spontaneous breathing (APRV), n = 13
Number of subjects: 37

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation with pressure support (SIMV), n = 10
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison between APRV and SIMV
Number of subjects: 37
Study: 17197130

Group type: EXPERIMENTAL
Intervention: Adequate RT (minimum radiation dose delivered: 4300 cGy for neoadjuvant RT or 4700 cGy for adjuvant RT; completion of RT in <44 days for neoadjuvant RT or <49 days for adjuvant RT)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Inadequate RT
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: No RT
Number of subjects: 788
Study: 15964867

Group type: EXPERIMENTAL
Intervention: Usual care plus event-recorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 12477219

Group type: EXPERIMENTAL
Intervention: MAGhaler dry powder inhaler with salbutamol (200 microg) at high peak inhaled flow rate (60 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MAGhaler dry powder inhaler with salbutamol (200 microg) at low peak inhaled flow rate (30 l/min)
Number of subjects: 10
Study: 10516187

Group type: EXPERIMENTAL
Intervention: Cycling for 1, 3, and 5 seconds
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cycling for 5 seconds at loads of 0, 25, 50, and 75 W
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tachycardia preceding hypotension
Number of subjects: 10
Study: 7881698

Group type: EXPERIMENTAL
Intervention: Dornase alfa (rhDNase), administered daily for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dornase alfa (rhDNase)
Number of subjects: 0
Study: 2039814

Group type: EXPERIMENTAL
Intervention: Fixed combination of nifedipine and atenolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Atenolol alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine retard and urinary recovery of nifedipine metabolite
Number of subjects: 15
Study: 7048247

Group type: EXPERIMENTAL
Intervention: Isaxonine, dosage: 1175 to 1500 mg/day, duration: 4 to 5 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 31939849

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg methadone for spinal surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methadone for cardiac surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 mg hydromorphone for spinal surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 μg/kg fentanyl for cardiac surgery
Number of subjects: 0
Study: 29254858

Group type: EXPERIMENTAL
Intervention: Screening group using the Fracture Risk Assessment Tool (FRAX)
Number of subjects: 6233

Group type: COMPARATOR
Intervention: Control group (usual management)
Number of subjects: 6233

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 6233
Study: 26584456

Group type: EXPERIMENTAL
Intervention: Topical Nigella sativa Seed Oil (600 mg applied to the site of pain bis in die for 2 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Topical Diclofenac (20 mg bis in die)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 24755148

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 22445438

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg, days 12-16)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg, days 8-14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily, days 8-14)
Number of subjects: 40
Study: 20064899

Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Zonnic
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 63
Study: 18077065

Group type: EXPERIMENTAL
Intervention: 7 weeks low-intensity wheelchair training (3 times a week, 70 min, at 30% of heart rate reserve)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7 weeks low-intensity wheelchair training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Experimental group (7 weeks training)
Number of subjects: 21
Study: 15677604

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12763985

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate (80 mg/day of elemental iron daily; n=75)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (n=69)
Number of subjects: 144
Study: 10781776

Group type: EXPERIMENTAL
Intervention: Distant healing for 6 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no distant healing)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Distant healing
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 8807068

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination therapy (ciprofloxacin and clarithromycin)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (ciprofloxacin alone)
Number of subjects: 5
Study: 1357070

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg oral, every 6 hours for 48 hours) + Pyridostigmine (120 mg oral) + GHRH (100 micrograms i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (2 mg oral, every 6 hours for 48 hours) + Placebo + GHRH (100 micrograms i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (oral, every 6 hours for 48 hours) + Placebo + GHRH (100 micrograms i.v.)
Number of subjects: 8
Study: 3899675

Group type: EXPERIMENTAL
Intervention: Citalopram 5 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Citalopram 25 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Citalopram 50 mg once daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Citalopram (various doses)
Number of subjects: 10
Study: 2953270

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram X kg‐1 X hr‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 microgram X kg‐1 X hr‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30